Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
-
Published:2022-11-02
Issue:1
Volume:128
Page:137-147
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Weir Ashley, Kang Eun-Young, Meagher Nicola S.ORCID, Nelson Gregg S., Ghatage PrafullORCID, Lee Cheng-Han, Riggan Marjorie J.ORCID, Gentry-Maharaj Aleksandra, Ryan Andy, Singh Naveena, Widschwendter MartinORCID, Alsop Jennifer, Anglesio Michael S., Beckmann Matthias W., Berger Jessica, Bisinotto Christiani, Boros Jessica, Brand Alison H., Brenton James D.ORCID, Brooks-Wilson Angela, Carney Michael E., Cunningham Julie M.ORCID, Cushing-Haugen Kara L., Cybulski Cezary, Elishaev Esther, Erber Ramona, Fereday Sian, Fischer Anna, Paz-Ares Luis, Gayarre Javier, Gilks Blake C., Grube Marcel, Harnett Paul R., Harris Holly R., Hartmann Arndt, Hein AlexanderORCID, Hendley Joy, Hernandez Brenda Y., Heublein Sabine, Huang Yajue, Huzarski Tomasz, Jakubowska AnnaORCID, Jimenez-Linan Mercedes, Kennedy Catherine J.ORCID, Kommoss Felix K. F.ORCID, Koziak Jennifer M., Kraemer Bernhard, Le Nhu D., Lesnock Jaime, Lester Jenny, Lubiński Jan, Menkiszak Janusz, Ney Britta, Olawaiye Alexander, Orsulic Sandra, Osorio AnaORCID, Robles-Díaz Luis, Ruebner Matthias, Shah Mitul, Sharma Raghwa, Shvetsov Yurii B., Steed Helen, Talhouk Aline, Taylor Sarah E., Traficante Nadia, Vierkant Robert A.ORCID, Wang Chen, Wilkens Lynne R., Winham Stacey J.ORCID, Benitez Javier, Berchuck Andrew, Bowtell David D.ORCID, Candido dos Reis Francisco J.ORCID, Cook Linda S., DeFazio AnnaORCID, Bowtell D., DeFazio A., Traficante N., Fereday S., Brand A., Harnett P., Sharma R., Doherty Jennifer A.ORCID, Fasching Peter A.ORCID, García María J.ORCID, Goode Ellen L., Goodman Marc T., Gronwald Jacek, Huntsman David G., Karlan Beth Y.ORCID, Kommoss Stefan, Modugno Francesmary, Schildkraut Joellen M., Sinn Hans-PeterORCID, Staebler Annette, Kelemen Linda E., Ford Caroline E.ORCID, Menon UshaORCID, Pharoah Paul D. P.ORCID, Köbel Martin, Ramus Susan J.ORCID,
Abstract
Abstract
Background
Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC.
Methods
Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis.
Results
Consistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HR = 0.78, 95% CI 0.67–0.91, p < 0.0001). GMNN protein expression was not significantly associated with overall HSGC patient survival. However, HGSCs with >35% GMNN expression showed a trend for better outcomes, though this was not significant.
Conclusion
We provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference37 articles.
1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505. 2. Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020;31:1240–50. 3. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307:382–90. 4. Ovarian Tumor Tissue Analysis C, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, et al. Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol. 2017;3:e173290. 5. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14:853–62.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|